Top Markets
Coin of the day
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation

ADMP
Rank in Stocks #38723
Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company... Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.
Share Price
$0.6241
Last synced: 2023-10-03
Market Cap
$836.88K
Change (1 day)
-2.10%
Change (1 year)
0.00%
Country
US
Trade Adamis Pharmaceuticals Corporation (ADMP)

Category

P/B ratio for Adamis Pharmaceuticals Corporation (ADMP)
P/B ratio as of 2026 TTM: 0
According to Adamis Pharmaceuticals Corporation latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Adamis Pharmaceuticals Corporation from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors